Cargando…

Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics

Levels of amyloid-beta monomer and deposited amyloid-beta in the Alzheimer’s disease brain are orders of magnitude greater than soluble amyloid-beta oligomer levels. Monomeric amyloid-beta has no known direct toxicity. Insoluble fibrillar amyloid-beta has been proposed to be an in vivo mechanism for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goure, William F, Krafft, Grant A, Jerecic, Jasna, Hefti, Franz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100318/ https://www.ncbi.nlm.nih.gov/pubmed/25045405 http://dx.doi.org/10.1186/alzrt272

Ejemplares similares

ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
por: Krafft, Grant A., et al.
Publicado: (2022)

An acute functional screen identifies an effective antibody targeting amyloid-β oligomers based on calcium imaging
por: Wang, Xueying, et al.
Publicado: (2018)

Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease
por: Lobello, Kasia, et al.
Publicado: (2012)

Alzheimer's disease therapeutic research: the path forward
por: Aisen, Paul S
Publicado: (2009)

The Beta-Amyloid Protein of Alzheimer's Disease: Communication Breakdown by Modifying the Neuronal Cytoskeleton
por: Mokhtar, Sara H., et al.
Publicado: (2013)

Amyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance
por: Marr, Robert A., et al.
Publicado: (2014)

Cessation of Neoangiogenesis in Alzheimer's Disease Follows Amyloid-beta Immunization
por: Biron, Kaan E., et al.
Publicado: (2013)

Amyloid Beta in Aging and Alzheimer’s Disease
por: Sehar, Ujala, et al.
Publicado: (2022)

Amyloid-beta Alzheimer targets — protein processing, lipid rafts, and amyloid-beta pores
por: Arbor, Sage C., et al.
Publicado: (2016)

Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease
por: Ding, Yu, et al.
Publicado: (2019)

Driving assessment in preclinical Alzheimer’s disease: progress to date and the path forward
por: Bayat, Sayeh, et al.
Publicado: (2022)

Editorial on, “Amyloid-beta clearance in Alzheimer's disease”
por: Marr, Robert A.
Publicado: (2014)

Amyloid Beta and MicroRNAs in Alzheimer’s Disease
por: Amakiri, Nnana, et al.
Publicado: (2019)

Amyloid-beta immunotherapy: the hope for Alzheimer disease?
por: Barrera-Ocampo, Alvaro, et al.
Publicado: (2016)

A Path Forward
por: Elkind, Mitchell S. V., et al.
Publicado: (2020)

Intracellular Accumulation of Amyloid-Beta – A Predictor for Synaptic Dysfunction and Neuron Loss in Alzheimer's Disease
por: Bayer, Thomas A., et al.
Publicado: (2010)

Fasting activates macroautophagy in neurons of Alzheimer’s disease mouse model but is insufficient to degrade amyloid-beta
por: Chen, Xigui, et al.
Publicado: (2015)

Immunotherapeutic Strategies for Alzheimer's Disease Treatment
por: Solomon, Beka
Publicado: (2009)

The amyloid beta ion channel hypothesis of Alzheimer’s disease
por: Shirwany, Najeeb A, et al.
Publicado: (2007)

Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
por: Cheignon, C., et al.
Publicado: (2017)

Impaired hepatic amyloid-beta degradation in Alzheimer’s disease
por: Maarouf, Chera L., et al.
Publicado: (2018)

Diversity of Amyloid-beta Proteoforms in the Alzheimer’s Disease Brain
por: Wildburger, Norelle C., et al.
Publicado: (2017)

Amyloid-Beta: A Crucial Factor in Alzheimer's Disease
por: Sadigh-Eteghad, Saeed, et al.
Publicado: (2015)

The Beta Amyloid Dysfunction (BAD) Hypothesis for Alzheimer’s Disease
por: Hillen, Heinz
Publicado: (2019)

Natural Products Targeting Amyloid Beta in Alzheimer’s Disease
por: Lee, Joo-Hee, et al.
Publicado: (2021)

Optical Imaging of Beta-Amyloid Plaques in Alzheimer’s Disease
por: Luo, Ziyi, et al.
Publicado: (2021)

Cardiometabolic Modification of Amyloid Beta in Alzheimer’s Disease Pathology
por: Hefner, Marleigh, et al.
Publicado: (2021)

Diagnosed Mild Cognitive Impairment Due to Alzheimer’s Disease with PET Biomarkers of Beta Amyloid and Neuronal Dysfunction
por: Hatashita, Shizuo, et al.
Publicado: (2013)

Glycogen and amyloid-beta: key players in the shift from neuronal hyperactivity to hypoactivity observed in Alzheimer's disease?
por: Bass, Britanny, et al.
Publicado: (2015)

TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance
por: Xiang, Xianyuan, et al.
Publicado: (2016)

A Path Forward for Reproducibility
Publicado: (2016)

Trans-Synaptic Spread of Amyloid-β in Alzheimer's Disease: Paths to β-Amyloidosis
por: Pignataro, Annabella, et al.
Publicado: (2017)

An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer’s disease: pyroglutamate amyloid beta
por: Vukicevic, M., et al.
Publicado: (2022)

Inhibition of Polo-like kinase 1 reduces beta-amyloid-induced neuronal cell death in Alzheimer's disease
por: Song, Bing, et al.
Publicado: (2011)

Butterbur Leaves Attenuate Memory Impairment and Neuronal Cell Damage in Amyloid Beta-Induced Alzheimer’s Disease Models
por: Kim, Namkwon, et al.
Publicado: (2018)

Human antibodies reactive with beta-amyloid protein in Alzheimer's disease
Publicado: (1993)

Investigating the effects of beta-amyloid on hippocampal signalling in Alzheimer's disease
por: Warburton, Julia M, et al.
Publicado: (2015)

Moving Away from Amyloid Beta to Move on in Alzheimer Research
por: Moreno-Treviño, María G., et al.
Publicado: (2015)

Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease
por: Moro, Maria Luisa, et al.
Publicado: (2018)

Simvastatin Efficiently Reduces Levels of Alzheimer’s Amyloid Beta in Yeast
por: Dhakal, Sudip, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8q2b0rvlf9kmmqi5er1qhbgnm2